Photo by scw1217 from unsplash
non-Hodgkin lymphomas extracutaneous the of and are indo-lent. 1,2 CD30 positivity may suggest the potential for large cell transformation and progression. 3 Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate… Click to show full abstract
non-Hodgkin lymphomas extracutaneous the of and are indo-lent. 1,2 CD30 positivity may suggest the potential for large cell transformation and progression. 3 Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate newly approved to treat CD30 + cutaneous lymphomas.
Keywords:
large cell;
cell transformation;
brentuximab extravasation
Journal Title: Dermatologic Therapy
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Dermatologic Therapy
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!